Intuitive Surgical, Inc. (NASDAQ:ISRG) Short Interest Update

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 3,220,000 shares, a decline of 5.6% from the March 31st total of 3,410,000 shares. Based on an average trading volume of 1,630,000 shares, the short-interest ratio is currently 2.0 days.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the transaction, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Robert Desantis sold 376 shares of the business's stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $375.39, for a total transaction of $141,146.64. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Mark Brosius sold 196 shares of the business's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Insiders have sold a total of 226,967 shares of company stock worth $87,848,586 over the last 90 days. Insiders own 0.80% of the company's stock.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors have recently bought and sold shares of ISRG. Van ECK Associates Corp grew its stake in shares of Intuitive Surgical by 2.1% during the 1st quarter. Van ECK Associates Corp now owns 57,675 shares of the medical equipment provider's stock worth $23,017,000 after acquiring an additional 1,162 shares during the period. HB Wealth Management LLC increased its position in shares of Intuitive Surgical by 10.7% during the 1st quarter. HB Wealth Management LLC now owns 5,980 shares of the medical equipment provider's stock valued at $2,387,000 after purchasing an additional 580 shares during the last quarter. Concord Wealth Partners grew its position in Intuitive Surgical by 498.6% during the 1st quarter. Concord Wealth Partners now owns 1,275 shares of the medical equipment provider's stock worth $509,000 after acquiring an additional 1,062 shares during the last quarter. Vest Financial LLC bought a new stake in shares of Intuitive Surgical in the 1st quarter worth approximately $307,000. Finally, Caprock Group LLC grew its position in shares of Intuitive Surgical by 5.8% in the 1st quarter. Caprock Group LLC now owns 5,455 shares of the medical equipment provider's stock worth $2,177,000 after buying an additional 301 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Trading Down 0.9 %

Intuitive Surgical stock traded down $3.52 during trading on Tuesday, hitting $370.62. 1,212,524 shares of the company were exchanged, compared to its average volume of 1,644,877. The business's 50 day moving average is $386.10 and its 200 day moving average is $347.50. Intuitive Surgical has a 52 week low of $254.85 and a 52 week high of $403.76. The company has a market capitalization of $131.46 billion, a P/E ratio of 66.90, a PEG ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. Intuitive Surgical's revenue was up 11.5% compared to the same quarter last year. Equities analysts expect that Intuitive Surgical will post 4.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Jefferies Financial Group lifted their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a "hold" rating in a research note on Friday, April 19th. BTIG Research lifted their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a "buy" rating in a research note on Friday, April 19th. Raymond James lifted their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the stock an "outperform" rating in a research note on Thursday, January 25th. Finally, Truist Financial lifted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and an average price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.